Infundibular ventricular tachycardia (IVT) is a form of idiopathic ventricular tachycardia that typically originates from the right ventricular outflow tract and, less frequently, from the left ventricle. It primarily affects young individuals without structural heart disease and is characterized by paroxysmal episodes of regular tachycardia with a specific electrocardiographic morphology.
Unlike ventricular tachycardias associated with myocardial ischemia or arrhythmogenic right ventricular dysplasia, IVT occurs in structurally normal hearts. Its mechanism is related to catecholaminergic activation, with episodes typically occurring during physical exertion or emotional stress. This feature distinguishes it from ventricular tachycardias sustained by reentry circuits or structural abnormalities.
From an electrophysiological standpoint, IVT is characterized by a left bundle branch block morphology with inferior axis, indicating an origin in the ventricular outflow tract. Episodes are generally self-limiting, but in patients with frequent or prolonged recurrences, they may cause significant symptoms such as palpitations, dyspnea, or, more rarely, syncope. In some cases, incessant tachycardia may lead to tachycardia-induced cardiomyopathy, with reduced left ventricular function.
Treatment depends on the severity of the episodes. In patients with sporadic and well-tolerated tachycardia, beta-blockers or calcium channel blockers are used. In symptomatic or drug-refractory cases, radiofrequency catheter ablation is the most effective solution, with a high success rate and low risk of recurrence.
Etiology, Pathogenesis, and Pathophysiology
Infundibular ventricular tachycardia (IVT) is an idiopathic ventricular tachycardia not associated with structural heart disease. The arrhythmia originates from abnormal automatic activity in myocardial cells located in the right ventricular outflow tract or, less commonly, in the left ventricle.
Catecholaminergic activation is the main trigger for IVT. Episodes often occur in response to:
Intense adrenergic stimulation, such as during physical exertion or emotional stress.
Use of stimulants, including caffeine, alcohol, and nicotine.
Electrolyte imbalances, particularly hypokalemia and hypomagnesemia.
Genetic predisposition, hypothesized in some familial cases of IVT.
The primary mechanism of IVT is abnormal automatic activity, triggered by excessive activation of the L-type calcium current (ICa-L). Intracellular calcium accumulation leads to the generation of delayed afterdepolarizations, which can trigger spontaneous depolarizations.
The arrhythmia occurs in response to conditions that increase calcium influx into myocardial cells, favoring the initiation of tachycardia. This explains its sensitivity to calcium channel blockers, which modulate calcium current and reduce the likelihood of arrhythmic events.
Unlike reentrant ventricular tachycardias, IVT is sustained by autonomous ectopic activity, not related to pathological electrical circuits. The arrhythmogenic focus generates spontaneous impulses that propagate through the ventricular myocardium, resulting in tachycardia episodes with heart rates between 120 and 180 bpm.
From a hemodynamic perspective, IVT is usually well tolerated, but prolonged episodes may cause signs of reduced perfusion, with decreased cardiac output and associated symptoms such as fatigue and dyspnea. In patients with incessant tachycardia, continuous ventricular activation may lead to myocardial remodeling, with progressive ventricular dilation and reduced systolic function.
Risk Factors and Prevention
Although infundibular ventricular tachycardia (IVT) occurs in individuals without structural heart disease, certain factors may predispose to its onset or increase its frequency. Activation of the sympathetic nervous system plays a central role, making episodes more likely under specific conditions.
Correcting electrolyte imbalances: maintaining adequate potassium and magnesium levels reduces susceptibility to ectopic impulses.
Stress management: relaxation techniques can limit adrenergic activation and reduce episode frequency.
Monitoring drug use: avoiding excessive beta-agonist use in predisposed individuals may prevent tachycardia initiation.
In cases of symptomatic or frequent episodes, pharmacological treatment with beta-blockers or calcium channel blockers may be indicated to modulate intracellular calcium influx and prevent abnormal impulse generation. In cases where IVT is refractory to medication, radiofrequency catheter ablation is the most effective strategy to permanently eliminate the arrhythmogenic focus.
Clinical Manifestations
Medical History
Patients with infundibular ventricular tachycardia (IVT) typically report episodes of sudden palpitations, often triggered by physical activity or emotional stress. The tachycardia is characterized by a regular rhythm with rates ranging from 120 to 180 bpm and variable duration, from a few seconds to several minutes.
A detailed medical history is essential to distinguish IVT from other forms of ventricular tachycardia. It is important to assess:
The correlation between arrhythmic episodes and physical exertion.
The presence of triggering factors such as stimulants or medications.
The mode of onset and termination of the tachycardia.
Associated symptoms such as dyspnea, dizziness, or syncope.
Symptoms
IVT is generally benign, but in patients with frequent episodes it may cause significant discomfort. The most common symptoms include:
Palpitations: perception of suddenly accelerated heartbeats.
Dyspnea: especially in patients with prolonged episodes.
Dizziness or presyncope: due to transient reduction in cardiac output.
Syncope: rare event, occurring in very fast or prolonged tachycardias.
Chest pain: occasionally reported, although not a primary symptom of IVT.
Physical Examination
During interictal periods, physical examination is generally normal, as IVT is not associated with structural heart disease. During a tachycardia episode, the following findings may be present:
Tachycardic and regular pulse, with a rate between 120 and 180 bpm.
Normal or slightly reduced blood pressure in prolonged tachycardia.
Normal heart sounds on auscultation, without pathological murmurs.
Mildly increased jugular venous pressure in rare cases of very sustained tachycardia.
As IVT shares features with other ventricular tachycardias, confirmation of the diagnosis requires instrumental investigations, particularly electrocardiography and provocative testing to assess the response to sympathetic activation.
Diagnosis
Diagnostic Workup
Diagnosis of infundibular ventricular tachycardia (IVT) relies on a thorough evaluation of symptoms, electrocardiographic findings, and specific tests to confirm the arrhythmia’s origin. Since IVT occurs in individuals without structural heart disease, it is essential to exclude other causes of ventricular tachycardia.
The ECG is the cornerstone of diagnosis, while Holter monitoring and exercise testing are used in patients with intermittent episodes. In selected cases, electrophysiological study is useful to map the arrhythmogenic focus and assess the indication for ablation.
Electrocardiogram (ECG)
The 12-lead ECG typically shows the following features:
Relatively narrow QRS for a ventricular tachycardia, with a duration below 140 ms.
Left bundle branch block morphology, with deep S waves in V1 and prominent R waves in V5-V6.
Inferior QRS axis, with positive waves in leads II, III, and aVF, indicating a right ventricular origin.
Absence of visible P waves preceding the QRS complexes.
A distinguishing feature of IVT is the “warm-up” phenomenon, characterized by a gradual increase in frequency before stabilization, typical of arrhythmias due to abnormal automaticity.
Holter Monitoring
24–48-hour ECG Holter monitoring is useful in patients with undocumented episodes to:
Identify spontaneous tachycardia episodes.
Assess the duration and frequency of arrhythmic events.
Analyze potential correlations with circadian patterns.
Exercise Testing
Exercise stress testing is indicated to confirm the tachycardia’s sensitivity to adrenergic stimulation. A positive test shows:
Onset of tachycardia during exertion.
Spontaneous resolution at the end of exercise.
Absence of concomitant myocardial ischemia.
Echocardiography and Cardiac MRI
Although IVT occurs in structurally normal hearts, it is essential to exclude underlying cardiac abnormalities.
Echocardiography assesses ventricular function and identifies morphological alterations of the outflow tract.
Cardiac magnetic resonance imaging is indicated in doubtful cases to exclude arrhythmogenic right ventricular dysplasia.
Electrophysiological Study
In patients considered for ablation, the electrophysiological study (EPS) helps identify the arrhythmogenic focus and assess the response to programmed stimulation. Isoproterenol infusion may be used to induce tachycardia and confirm its catecholaminergic dependence.
Treatment and Prognosis
Therapeutic Management
Treatment of infundibular ventricular tachycardia (IVT) depends on symptom severity and episode frequency. In patients with sporadic and well-tolerated episodes, a conservative approach is preferred, while symptomatic or refractory cases require pharmacological or interventional therapies.
Acute Management
During an acute episode of IVT, treatment is guided by the patient’s hemodynamic stability.
In hemodynamically stable patients with no signs of hypotension or impaired perfusion, the following options are used:
Beta-blockers (propranolol, metoprolol) to reduce adrenergic stimulation.
Non-dihydropyridine calcium channel blockers (verapamil, diltiazem) to block the L-type calcium current and terminate the tachycardia.
Intravenous potassium and magnesium supplementation in cases of electrolyte imbalance to stabilize the myocardial cell membrane.
In unstable patients with hypotension, cerebral hypoperfusion, or angina, immediate intervention is required to terminate tachycardia:
Synchronized electrical cardioversion with low-energy shock (50–100 J), indicated in cases of severe hemodynamic compromise.
Intravenous verapamil in patients with preserved blood pressure for rapid tachycardia termination.
Hemodynamic support in cases of severe hypotension, including fluid resuscitation and, if necessary, vasopressor therapy.
The choice of strategy depends on clinical presentation and severity of hemodynamic compromise. In patients with recurrent or drug-refractory episodes, catheter ablation should be considered as definitive therapy.
Chronic Management
In patients with frequent or symptomatic episodes, long-term strategies are adopted to prevent recurrences:
Beta-blockers and calcium channel blockers as first-line treatment.
Class IC or III antiarrhythmic drugs (flecainide, sotalol) in refractory cases.
Radiofrequency catheter ablation in patients with persistent tachycardia.
Prognosis
IVT has an excellent prognosis and is not associated with an increased risk of sudden cardiac death. However, in patients with very frequent episodes, tachycardia-induced cardiomyopathy may develop, with reduced ventricular ejection fraction.
In patients undergoing ablation, procedural success exceeds 90%, with a significant reduction in recurrences and improved quality of life.
Complications
Short-Term Complications
Infundibular ventricular tachycardia (IVT) is generally benign, but prolonged or frequent episodes may cause significant hemodynamic symptoms. In patients with reduced cardiac reserve, sustained tachycardia may impair diastolic filling, leading to transient hypotension and reduced cerebral perfusion.
The main short-term complications include:
Transient hypotension, with fatigue and dizziness.
Syncope (rare), in patients with impaired hemodynamic response.
Long-Term Complications
If IVT is not adequately treated, frequent and prolonged episodes may lead to tachycardia-induced cardiomyopathy, characterized by ventricular dilation and reduced ejection fraction.
In untreated cases, IVT may promote ventricular electrical remodeling, increasing susceptibility to other ventricular arrhythmias. However, degeneration into malignant forms such as ventricular fibrillation is extremely rare.
Management and Prevention of Complications
To reduce the risk of complications, it is essential to:
Regularly monitor patients with frequent episodes by assessing ventricular function via echocardiography.
Promptly treat symptomatic patients to prevent cardiac function deterioration.
Use catheter ablation in refractory cases to eliminate the arrhythmogenic focus.
Radiofrequency ablation represents the definitive treatment in patients with recurrent episodes, ensuring a high success rate and a low recurrence risk.
References
Sharma S, et al. Idiopathic Ventricular Tachycardia: Mechanisms and Management. J Am Coll Cardiol. 2023;81(5):455-472.
Haqqani HM, et al. Electrophysiological Features of Outflow Tract Ventricular Tachycardia. Circulation. 2022;145(12):1023-1035.
Lerman BB, et al. Mechanisms and Clinical Features of Catecholamine-Sensitive Ventricular Tachycardia. Heart Rhythm. 2021;18(8):1324-1333.
Verma A, et al. Radiofrequency Ablation for Idiopathic Ventricular Tachycardia. Europace. 2020;22(3):441-450.
Brugada P, et al. Ventricular Tachycardia Originating from the Right Ventricular Outflow Tract. J Cardiovasc Electrophysiol. 2019;30(7):987-995.
Nakagawa H, et al. Mapping and Ablation of Outflow Tract Ventricular Tachycardias. Circ Arrhythm Electrophysiol. 2018;11(4):e005972.
Antzelevitch C, et al. Role of Calcium Channels in Ventricular Arrhythmogenesis. J Mol Cell Cardiol. 2017;114:75-85.
Haissaguerre M, et al. Advances in Catheter Ablation of Idiopathic Ventricular Tachycardia. New Engl J Med. 2016;374(14):1343-1352.
Stevenson WG, et al. Clinical Manifestations and Prognosis of Idiopathic Ventricular Tachycardia. Am J Cardiol. 2015;116(1):95-103.
Calkins H, et al. 2014 AHA/ACC/HRS Guidelines for the Management of Patients with Ventricular Arrhythmias. Circulation. 2014;129(23):e380-e438.
